A metabotropic glutamate receptor antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

DL-AP3

Item No. 13852

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3-phosphono-alanine
CAS Number
5652-28-8
Synonyms
  • DL-2-Amino-3-Phosphonopropionic Acid
  • NSC 30078
Molecular Formula
C3H8NO5P
Formula Weight
169.1
Purity
≥95%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 2 mg/ml
SMILES
NC(CP(O)(O)=O)C(O)=O
InChi Code
InChI=1S/C3H8NO5P/c4-2(3(5)6)1-10(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)
InChi Key
LBTABPSJONFLPO-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    50 mg

    $41

    Add

    100 mg

    $75

    Add
    Product Description

    DL-AP3 is a competitive mGluR1 antagonist that demonstrates a Ki value of 298 μM and an IC50 value of 1mM for rat mGluR1α when challenged with glutamate.1 DL-AP3 can antagonize excitatory amino acid-induced phosphoinositide hydrolysis, induce Ca2+ mobilization in rat hippocampal slices, and inhibit phosphoserine phosphatase in rat brain cortex.2,3 At concentrations from 10-300 μM DL-AP3 has been used to characterize the role of mGluR in long-term potentiation in the hippocampus in a model of learning and memory, the release of glutamate in Parkinson’s disease, and the increased activity of mGluR implicated in fragile X syndrome.4,5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Schoepp, D.D., Jane, D.E., and Monn, J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38(10), 1431-1476 (1999).

    2. Schoepp, D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299(1), 12-20 (2001).

    3. Hawkinson, J.E., Acosta-Burruel, M., and Wood, P.L. The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur. J. Pharmacol. 307, 219-225 (1996).

    4. Otani, S., Connor, J.A., and Levy, W.B. Long-term potentiation and evidence for novel synaptic association in CA1 stratum oriens of rat hippocampus. Learn. Mem. 2(2), 101-106 (1995).

    5. Hao, L., Ding, J.H., and Hu, G. Group I mGluR ligands fail to affect 6-hydroxydopamine-induced death and glutamate release of PC12 cells. Acta Pharmacol. Sin. 24(7), 641-645 (2003).

    6. Xu, Z.H., Yang, Q., Feng, B., et al. Group I mGluR antagonist rescues the deficit of D1- induced LTP in a mouse model of fragile X syndrome. Mol. Neurodegener. 7(1), (2012).